Payers

Canada’s efforts to reduce pharmaceutical prices should not come at the cost of contributing our fair share to developing new treatment innovations, and should rely more on negotiations with manufacturers than regulation.

NICE is changing how it assess new drugs, devices, diagnostics and digital technologies to provide faster and fairer access in the NHS. The changes will also improve the way it works with patients, the NHS and the life sciences industry.

For an increasingly important set of drugs, Medicare has been driving up prices. It knows how to do better.

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”.

The National Institute for Health and Care Excellence, the United Kingdom’s watchdog on the value of drugs, issued draft guidance recommending Novartis’ midostaurin to treat advanced systemic mastocytosis in adults.

In a release, NICE said that it needs more conversations with patient groups and professionals so that the advice offered is further supported.

The Appeal Court’s unanimous decision demonstrates that the Patented Medicine Prices Review Board is out of control in an anti-industry, anti-patient witch-hunt.

EU stimulus funding marks opportunity to establish health technology appraisal agency in Spain.

Paper by Bentley University researchers and West Health considers the impact of drug pricing reforms on large and small biopharma companies if Medicare is authorized to negotiate drug prices.

Stefan Strecko says he's pleaded with Canada Life to cover cost of 'miracle' drug.

Spending review says that confidential pricing deals make it more difficult for HSE to contain drug costs.

NICE declares Lilly’s breast cancer drug to be cost-effective, allowing routine use on the NHS.

In explaining the move, the biotech complained that it has become a losing proposition trying to convince European Union member states to make large upfront payments for therapies that can save health care systems much higher costs later.

A breast cancer drug that was rejected for routine NHS use in England earlier this year has now been recommended by health officials after a discount was agreed with the manufacturer.

The Pharmaceutical Care Management Association, an organization representing pharmacy benefit managers, has sued the federal government in an effort to block a rule requiring them to disclose the net prices they negotiate with drug companies.